Grace Therapeutics GRCE
NASDAQ GRCE
$2.15 +0.01 (+0.47%)
As of: Aug 21, 2026 · 9:42 AM EDT

Grace Therapeutics (GRCE) Operating Leases (2020 - 2023)

Grace Therapeutics (GRCE) posted Operating Leases of $46000.0 for Q3 2023, down 90.52% sequentially from $485000.0 in Q1 2023, and down 89.78% YoY from $450000.0 in Q3 2022.

Grace Therapeutics (GRCE) Operating Leases (2020 - 2023) Analysis & Trends

Grace Therapeutics has reported Operating Leases for 3 years, with the latest figure at $46000.0 in Q3 2023.

  • Quarterly Operating Leases fell 89.78% year-over-year to $46000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $46000.0 (down 89.78% YoY) and the FY2023 annual result came in at $485000.0, up 153.93% from the prior year.
  • Operating Leases eased to $46000.0 in Q3 2023 per GRCE's latest filing, from $485000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $485000.0 in Q1 2023 and troughed at $38000.0 in Q3 2020.
  • A 3-year average of $215666.7 and a median of $174000.0 in 2022 frame the typical range for Operating Leases.
  • The widest YoY moves for Operating Leases: up 153.93% in 2023, down 89.78% in 2023.
  • Over 3 years, Operating Leases stood at $38000.0 in 2020, then surged by 1031.58% to $430000.0 in 2022, then tumbled by 89.3% to $46000.0 in 2023.
  • According to Business Quant data, Operating Leases over the past three periods registered $46000.0, $485000.0, and $430000.0 for Q3 2023, Q1 2023, and Q4 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.04 Bn 130.18 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.98 Bn 77.98 Bn 3.93 Bn
3 Argenx Se 64.37 Bn 59.19 Bn 1.37 Bn
4 Moderna 57.67 Bn 52.53 Bn 52.00 Mn
5 BeOne Medicines 41.94 Bn 36.84 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
7 BioNTech SE 27.75 Bn 9.35 Bn 668.28 Mn
8 Insmed 27.24 Bn 26.08 Bn 358.27 Mn
9 Royalty Pharma 27.03 Bn 26.20 Bn -
10 Grace Therapeutics 37.13 Mn 37.13 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 46,000.00
Mar 31, 2023 485,000.00
Dec 31, 2022 430,000.00
Sep 30, 2022 450,000.00
Jun 30, 2022 174,000.00
Mar 31, 2022 191,000.00
Sep 30, 2020 38,000.00
Jun 30, 2020 56,000.00
Mar 31, 2020 71,000.00